"Empowering Immunity Through Precision Diagnostics"
Welcome to MOL Diagnostics,
Your Partner in Transformative Immune Diagnostics. Setting up and operating a diagnostic laboratory in Australia requires navigating complex regulatory pathways and meeting stringent accreditation requirements. At MOL Diagnostics, we are on a journey to establish a cutting-edge diagnostic lab dedicated to advancing immune-related diagnostics while adhering to the highest standards of quality and compliance.
Join us as we work towards redefining healthcare with innovation, precision, and a commitment to excellence.
About Us
Our Mission
At MOL Diagnostics, our mission is to revolutionize the diagnosis of immune-related disorders, providing clinicians with the tools they need for early, accurate, and personalized patient care.
Our Vision
We aim to become a leading diagnostic laboratory in Australia, known for pioneering advanced immunological tests and fostering collaborations that drive innovation in healthcare.
Our focus
On integrating state-of-the-art technology, including Luminex platforms and Illumina, ensures accuracy and efficiency in every test we conduct.
About Us
Innovative Diagnostic Services
We specialize in cutting-edge diagnostic solutions, including:
-
Tumor Immunotherapy Profiling: Tailoring immunotherapy approaches through comprehensive biomarker panels.
-
Autoimmune Disease Diagnostics: Advanced assays like indirect immunofluorescence (IIF) and anti-phospholipid syndrome (APS) panels.
-
Molecular Allergy Testing: Utilizing technologies like Using Luminex xMAP® Technology for precise allergen identification.
-
Next-Generation Sequencing (NGS): Genetic profiling for immune-deficiencies and immune system disorders.
-
Specialized Lymphocyte Culture Assays: For delayed-type hypersensitivity (DTH) testing and mitogen responses.
Panel List Tests
At MOL Diagnostics, we offer a comprehensive suite of specialized diagnostic services tailored to meet the needs of clinicians and patients in the field of immunology. Utilizing cutting-edge technology and innovative methodologies, our lab provides reliab
1. Autoimmune panel
-
Autoantibody Testing
-
Anti-Nuclear Antibodies (ANA) via Indirect Immunofluorescence (IIF)
-
Anti-ENA (Extractable Nuclear Antigen) Panel (e.g., SSA, SSB, Sm, RNP)
-
Anti-dsDNA Antibodies
-
Anti-CCP (Cyclic Citrullinated Peptide) for Rheumatoid Arthritis
-
Anti-Phospholipid Antibodies (aCL, β2GP1, and Lupus Anticoagulant)
-
-
Disease-Specific Autoantibodies
-
Anti-GBM for Goodpasture’s Syndrome
-
Anti-Liver-Kidney Microsomal (LKM) Antibodies
-
Anti-Mitochondrial Antibodies (AMA) for Primary Biliary Cholangitis
-
Anti-Glutamic Acid Decarboxylase (GAD) Antibodies for Type 1 Diabetes
-
Anti-TPO and Anti-Tg for Thyroid Autoimmunity
-
-
Paraneoplastic Neurological Syndromes (PNS) Panel
-
Hu, Yo, Ri, Ma2, CV2, Amphiphysin, and SOX1 Antibodies
-
IIF to detect neuron-specific autoantibodies using brain tissue substrates
-
-
Neurology-Associated Autoimmunity
-
Aquaporin-4 Antibodies (NMO Spectrum Disorder)
-
Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies
-
Anti-LGI1 and CASPR2 for Autoimmune Encephalitis
-
Hyper sensitivity Panel
-
Specific IgE Testing
-
Molecular Diagnosis with ImmunoCAP for individual allergens
-
Component-Resolved Diagnostics (CRD)
-
-
Basophil Activation Test (BAT)
- Cellular assay for immediate hypersensitivity
-
Eosinophil Cationic Protein (ECP) Measurement
- Marker for allergic inflammation
-
Tryptase Measurement for Mast Cell Disorders
-
Lymphocyte Culture for DTH Testing
Genetic and Molecular Diagnostics Panel
1. Next-Generation Sequencing (NGS)
o Gene Panel for Primary Immunodeficiency Disorders (e.g., STAT3, FOXP3)
o Autoimmune Poly-endocrine Syndrome Gene Panels
o HLA Typing for Autoimmune and Transplant Applications
2. PCR-Based Testing
o Quantitative PCR for Epstein-Barr Virus (EBV) in autoimmune contexts
o TCR/BCR Clonality Assays
Other Advanced Diagnostic Tools
- Immunoelectrophoresis and Immunofixation
Detection of Monoclonal Gammopathies
- Cytokine Panels
ELISA or Flow Cytometry-Based Assays for Inflammatory Markers (e.g., IL-6, TNF-α)
- Complement Testing
CH50 Assay for Complement Activity
C3 and C4 Levels
- Cellular Damage and Apoptosis
Aclides System for Advanced Cell Damage Detection
5. Cell-Mediated Immune Cytotoxicity (CMIC) Assay
Tumor Immunotherapy Profiling Panel
-
Neoantigen Profiling
- Next-Generation Sequencing (NGS): Whole-exome and transcriptome sequencing.
-
Immune Checkpoint Biomarker Tests
-
PD-L1/PD-1 Expression Assay (IHC and Flow Cytometry).
-
Tumor Mutational Burden (TMB) Analysis (NGS).
-
Microsatellite Instability (MSI) Testing (PCR/NGS).
-
-
T-Cell Repertoire Analysis
-
TCR Sequencing (TCR-Seq).
-
Single-Cell RNA Sequencing for immune profiling.
-
-
Cytokine and Immune Signature Testing
-
Multiplex Immunoassays (e.g., Luminex panels for cytokines and chemokines).
-
Nanostring Immune Profiling Gene Panels.
-
-
Functional Assays
-
ELISPOT for IFN-γ production.
-
Immune Cell Cytotoxicity Assay.
-
-
Flow Cytometry Studies
- Advanced immune phenotyping for checkpoint and activation markers.
Why Tumor Immunotherapy Profiling Matters
📌 Did you know?
✔️ Only 20-40% of cancer patients respond effectively to immunotherapy.
✔️ Biomarkers like PD-L1 expression, Tumor Mutational Burden (TMB), and immune cell infiltration can predict response.
✔️ Personalized profiling reduces unnecessary treatments and side effects while improving outcomes.
📌Our Approach at MOL Diagnostics
We use state-of-the-art
biomarker-driven diagnostics to improve immunotherapy precision.
🔬 Technologies We Use:
✔️ Next-Generation Sequencing (NGS): Identifies genetic and mutational markers. ✔️ Multiplex Immunoassays: Measures immune responses and cytokine levels. ✔️ AI-Driven Data Analysis: Enhances biomarker discovery and clinical insights.
📌Real-World Impact: Case Studies
📖 Case Study 1: Predicting Response to Checkpoint Inhibitors
🔹 Patient Profile: 55-year-old with metastatic lung cancer.
🔹 Findings: High PD-L1 expression and elevated TMB suggest strong response to PD-1 inhibitors.
🔹 Outcome: Immunotherapy led to significant tumor shrinkage and long-term remission.
📖 Case Study 2: Avoiding Unnecessary Immunotherapy
🔹 Patient Profile: 48-year-old with melanoma.
🔹 Findings: Low PD-L1 and minimal immune infiltration suggest poor response likelihood.
🔹 Outcome: Clinician opted for a targeted therapy approach, leading to better patient outcomes
Biography
Welcome to MOL Diagnostics, a visionary startup dedicated to delivering transformative diagnostics for immune-related disorders. Founded by Dr. Sheikh Sajjadieh M, a highly accomplished immunologist with over 15 years of expertise in medical science laboratories, MOL Diagnostics is driven by a commitment to innovation and precision in healthcare.
Dr. Sajjadieh brings a unique perspective as a refugee and a member of the Australian Institute of Medical and Clinical Scientists (AIMS). His journey exemplifies resilience, dedication, and a passion for advancing immunological research and diagnostics in Australia.
The motivation for starting this project stems from my deep expertise in immunology, my personal and professional experiences, and the identified gaps in current diagnostic capabilities for immune-related disorders.
Key Motivations
Professional Expertise and Passion: With over 15 years of experience in immunology and clinical laboratory science, I have a strong desire to apply my skills to improve diagnostics. My expertise in immune dysfunction and autoimmune disorders has shown me the unmet needs in accurate and early diagnostic methods, particularly in Australia.
Unmet Needs in Immunology Diagnostics:
There are limited advanced diagnostic labs in Australia offering comprehensive tests such as Tumor Immunotherapy Profiling, Cytokine Profiling, or Pharmacogenomics for Biologic Therapies.
Delayed or inaccurate diagnosis of immune-related conditions affects patient outcomes significantly.
Personal Motivation and Refugee Background: As someone with a refugee background, I understand the barriers to accessing healthcare and the need for affordable, precise, and innovative diagnostics. This lab is not just a professional endeavor but a way to contribute meaningfully to society.
Transforming Healthcare Outcomes: My project aims to bridge the gap between cutting-edge research and clinical application, ensuring patients benefit from the latest advancements in immunology diagnostics. By focusing on collaboration with healthcare providers and researchers, I envision improving diagnostic accuracy and therapeutic outcomes.
Partner with MOL Diagnostics
At MOL Diagnostics, we are committed to revolutionizing immune-related diagnostics through innovation and collaboration. We invite strategic partnerships with organizations that share our vision of advancing healthcare through cutting-edge technology and research.
Why Partner with Us?
-
Proven Expertise: With over 15 years of experience in immunology and diagnostics, we are well-equipped to demonstrate the value of advanced technologies in real-world clinical applications.
-
Strategic Location: Operating in Melbourne, a hub for medical innovation, we provide unparalleled access to the Australian and Asia-Pacific markets.
-
Innovation-Driven: We focus on transformative diagnostics, including immune profiling, autoimmune testing, and novel diagnostic assays.
Partnership Opportunities We are actively seeking partnerships in the following areas:
-
Technology Integration: Showcase your diagnostic technologies in our advanced laboratory.
-
Collaborative Research: Partner with us on research projects to evaluate and promote innovative solutions.
-
Co-Branded Workshops and Training: Educate healthcare professionals about cutting-edge diagnostic techniques.
-
Market Expansion: Leverage our network to expand your reach in Australia and beyond.
Our Team
Dr Mohammadreza Sheikh Sajjadieh PhD, AIMS, Clinical Immunology & Allergy
Founder
Exciting News: MOL Diagnostics Founder Nominated for the Governor of Victoria Startup Awards 2025
We are thrilled to announce that Dr. Sheikh Sajjadieh M, founder of MOL Diagnostics, has been nominated for the prestigious Governor of Victoria Startup Awards 2025 in the category of Ecosystem Hero of the Year.
This nomination is a testament to our dedication to advancing biotechnology, supporting startups, and driving medical innovation in Victoria.
Recognizing Leadership in the Victorian Startup Ecosystem
The Governor of Victoria Startup Awards, powered by LaunchVic, celebrates the State’s most outstanding founders, investors, scaleups, and community builders who have made a significant impact in the startup ecosystem. Being nominated in the Ecosystem Hero of the Year category highlights our efforts in: ✔️ Supporting early-stage biotech and medtech startups with laboratory expertise and resources. ✔️ Advancing tumor immunotherapy profiling and precision diagnostics for better patient outcomes. ✔️ Mentoring emerging entrepreneurs in medical research and healthcare innovation. ✔️ Contributing to the growth of Victoria’s biotech and startup ecosystem.
Our Commitment to Innovation & Collaboration
At MOL Diagnostics, we are committed to building a stronger, more collaborative startup environment in Victoria. This nomination further fuels our mission to: 🔬 Facilitate access to cutting-edge laboratory technologies for biotech startups. 🔗 Build strategic partnerships with universities, research institutes, and industry leaders. 🚀 Drive scientific entrepreneurship and commercialization in medical research.
Innovative Diagnostics in Immunology that MOL Diagnostics would be equipped
Illumina MiSeq
The MiSeq is a benchtop next-generation sequencing (NGS) platform
Ion GeneStudio S5 System
The Ion GeneStudio S5 is a versatile NGS platform from Thermo Fisher Scientific, capable of sequencing a wide range of targets
Luminex xMAP® Technology
Luminex xMAP Technology is a multiplexing platform that allows simultaneous analysis of multiple analytes in a single sample using color-coded beads.
The AKLIDES® system by Medipan Gmb
An automated imaging platform designed for the analysis of immunofluorescence assays (IFA), particularly in the diagnosis of autoimmune diseases.
Common questions
-
Luminex Platforms: Multiplex bead-based assays for efficient cytokine and biomarker profiling.
-
Flow Cytometry: Quantitative and qualitative immune cell analysis.
-
Automated Immunofluorescence Scanning Systems: Ensuring accuracy and speed in autoimmune diagnostics.
-
Immunoelectrophoresis and PCR: For precise molecular-level diagnostics.
-
Next-Generation Sequencing (NGS): Genetic profiling for immunodeficiencies and immune system disorders
We welcome researchers, clinicians, and companies to join us in driving innovation in immunological diagnostics.
-
Collaborations: Partner with us for academic and clinical studies in autoimmune, allergy, and immune-oncology research.
-
Industry Engagements: We work with leading biotech and pharmaceutical companies to co-develop diagnostic tools.
"Our lab uniquely combines state-of-the-art technologies such as Luminex, NGS, and advanced immunofluorescence with niche services like Tumor Immunotherapy Profiling, cytokine analysis, and DTH testing. We also focus on underserved areas like autoimmune diagnostics in oncology."
"We plan to complete the setup and obtain NATA accreditation within 12-18 months after securing funding, with initial operations starting shortly thereafter."
Contact Us
Logos